XCOPRI University | APP Login

Courses
Mission
APP Connect
Library
Log in
Enroll

Log in

Email This field is required.

Password

Forgot password?

Not a student of XCOPRI University yet?

Enroll

INDICATION

XCOPRI^® (cenobamate tablets) CV is indicated for the treatment of partial-onset seizures in adult patients.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XCOPRI^® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

For US Healthcare Professionals Only

Prescribing Information Medication Guide HCP Site Patient Site

For US Healthcare Professionals Only

INDICATION and IMPORTANT SAFETY INFORMATION for XCOPRI^® (cenobamate tablets) CV

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

CONTRAINDICATIONS

XCOPRI^® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end‑stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment.

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

Please see Full Prescribing Information.

All content on the XCOPRI University site is provided for general information and educational purposes only and should not be considered the exclusive source for this type of information. The content is intended to assist medical professionals in enhancing their knowledge of a specific practice area, and should not be considered a replacement for professional medical training. This informational content does not replace or supersede approved labeling guidelines. Every effort has been made by the owner to ensure the information contained within this website is accurate and complete, but owner does not make any warranties as to the fitness of this information.

This website is intended for Advanced Practice Providers and is not intended for patients or consumers. The content herein is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Patients can access more information on XCOPRI at www.XCOPRI.com.

Prescribing Information
Medication Guide
HCP Site
Patient Site

Request a Representative
About SKLSI
Contact Us
Privacy Policy
Your Privacy Choices
Legal Notices
Site Map

For US Healthcare Professionals Only

XCOPRI^® is the registered trademark of SK Life Science, Inc. Other registered trademarks are the property of their respective owners.

For any medical questions or to report an adverse event, please contact Medical Information at 1-866-657-5574.

© 2023 SK Life Science, Inc., a subsidiary of
SK Biopharmaceuticals Co., Ltd.

PM-US-XCOP-1079 11/23

Thank you for visiting.

You are about to leave this site.

GO STAY

Select at least one option

Loading...

Enroll for free!

You must enroll in XCOPRI University to access courses, features, and resources.

Enroll Today

Success!

Check your inbox.

Congratulations!

You’re now a member of XCOPRI University. Make sure to check out your New Student badge in your profile.

Thank you

An invitation email has been sent to your colleague.

Error!

Email or Password is incorrect.